用于接受术后放(化)疗的HPV阴性局部晚期头颈鳞癌患者局部区域控制预后的6基因特征谱的开发与验证
本研究利用机器学习方法从全转录组数据中开发并验证一个新型基因特征谱,用于预测接受术后放(化)疗的HPV阴性局部晚期头颈鳞癌患者的局部区域控制。在多中心回顾性训练队列128例和独立验证队列114例中,识别出由CAV1、GPX8、IGLV3-25、TGFBI四个基因及INHBA与SERPINE1组成的荟萃基因构成的6基因特征谱,该特征谱在训练数据中预后价值ci=0.84,验证中ci=0.63,并将患者显著分层为两个风险组(p=0.005)。
要点
- 6基因特征谱由CAV1、GPX8、IGLV3-25、TGFBI及INHBA与SERPINE1荟萃基因组成。
- 训练队列ci=0.84,验证队列ci=0.63,风险分层p=0.005。
- 联合T分期、肿瘤部位、CD44及15基因缺氧特征谱后验证ci=0.69,p=0.001。
核心结论
- 开发并验证了一个新型预后6基因特征谱,用于接受术后放(化)疗的HPV阴性头颈鳞癌患者的局部区域控制。
- 该特征谱在成功的前瞻性验证后可用于放疗个体化的临床试验。
研究设计与样本
- 多中心回顾性训练队列128例,独立验证队列114例,均来自德国癌症联盟-放射肿瘤学组(DKTK-ROG)。
- 使用Affymetrix GeneChip Human Transcriptome Array 2.0进行基因表达分析,基于差异基因表达分析和Cox回归筛选基因。
- 技术验证采用nanoString技术。
主要发现
- 识别出6基因特征谱,包含CAV1、GPX8、IGLV3-25、TGFBI四个基因及INHBA与SERPINE1组成的荟萃基因。
- 该特征谱在训练数据中对局部区域控制具有预后价值(ci=0.84),在验证中ci=0.63,并将患者显著分层为两个风险组(p=0.005)。
- 将6基因特征谱与临床参数T分期和肿瘤部位以及癌症干细胞标志物CD44和15基因缺氧相关特征谱联合,提高了验证性能(ci=0.69,p=0.001)。
关键数值与推荐
- 训练数据中6基因特征谱预后局部区域控制的ci=0.84。
- 验证数据中6基因特征谱预后局部区域控制的ci=0.63,风险分层p=0.005。
- 联合临床参数、CD44和15基因缺氧特征谱后验证ci=0.69,p=0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to develop and validate a novel gene signature from full-transcriptome data using machine-learning approaches to predict loco-regional control (LRC) of patients with human papilloma virus (HPV)-negative locally advanced head and neck squamous cell carcinoma (HNSCC), who received postoperative radio(chemo)therapy (PORT-C). MATERIALS AND METHODS: Gene expression analysis was performed using Affymetrix GeneChip Human Transcriptome Array 2.0 on a multicentre retrospective training cohort of 128 patients and an independent validation cohort of 114 patients from the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Genes were filtered based on differential gene expression analyses and Cox regression. The identified gene signature was combined with clinical parameters and with previously identified genes related to stem cells and hypoxia. Technical validation was performed using nanoString technology. RESULTS: We identified a 6-gene signature consisting of four individual genes CAV1, GPX8, IGLV3-25, TGFBI, and one metagene combining the highly correlated genes INHBA and SERPINE1. This signature was prognostic for LRC on the training data (ci = 0.84) and in validation (ci = 0.63) with a significant patient stratification into two risk groups (p = 0.005). Combining the 6-gene signature with the clinical parameters T stage and tumour localisation as well as the cancer stem cell marker CD44 and the 15-gene hypoxia-associated signature improved the validation performance (ci = 0.69, p = 0.001). CONCLUSION: We have developed and validated a novel prognostic 6-gene signature for LRC of HNSCC patients with HPV-negative tumours treated by PORT-C. After successful prospective validation the signature can be part of clinical trials on the individualization of radiotherapy.
引用
- Patil S, Linge A, Grosser M, et al. Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiother Oncol. 2022. PMID: 35429503. doi:10.1016/j.radonc.2022.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。